Drugs / amiselimod
amiselimod
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02307643 | Feb 2015 → May 2017 | systemic lupus erythematosus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02310048 | Nov 2014 → Mar 2015 | relapsing-remitting multiple sclerosis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02293967 | Sep → Dec 2014 | relapsing-remitting multiple sclerosis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02148185 | May → Jun 2014 | Crohn disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01666327 | Jun 2012 → Jul 2014 | inflammatory bowel disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02193217 | ? → Dec 2014 | relapsing-remitting multiple sclerosis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04857112 | Sep 2021 → Sep 2024 | ulcerative colitis | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02389790 | Aug 2015 → Aug 2017 | Crohn disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02378688 | Mar 2015 → Oct 2016 | Crohn disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01987843 | Sep 2013 → Sep 2014 | psoriasis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01890655 | Aug 2013 → Mar 2016 | relapsing-remitting multiple sclerosis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01742052 | Jan 2013 → Jul 2014 | relapsing-remitting multiple sclerosis | Tanabe Pharma Corporation | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amiselimod | “Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study.” PMID 30231665 ↗ Dec 2018 |
| Known as | 2240442 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707375 ↗ |
| Known as | AMISELIMOD HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707375 ↗ |
| Known as | MT-1303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02389790 ↗ |
| Known as | MT-1303 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707375 ↗ |
| Modality | Small molecule | — CHEMBL3707375 ↗ |
| Route | Oral | “single oral dose of MT-1303” NCT01666327 ↗ |